Zacks Research Analysts Lift Earnings Estimates for CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities research analysts at Zacks Research boosted their Q4 2024 EPS estimates for Corcept Therapeutics in a research report issued to clients and investors on Wednesday, November 20th. Zacks Research analyst K. Das now forecasts that the biotechnology company will post earnings of $0.28 per share for the quarter, up from their prior estimate of $0.26. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2025 earnings at $0.41 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.56 EPS, Q3 2026 earnings at $0.70 EPS and FY2026 earnings at $2.38 EPS.

Several other research firms have also issued reports on CORT. Piper Sandler increased their price target on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 18th. Sandler O’Neill reaffirmed a “buy” rating on shares of Corcept Therapeutics in a report on Friday, October 18th. Truist Financial boosted their price target on Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a report on Monday, September 30th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Corcept Therapeutics in a research note on Thursday, October 31st. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $38.00 target price on shares of Corcept Therapeutics in a research note on Tuesday, July 30th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $65.25.

Corcept Therapeutics Trading Up 2.9 %

Shares of Corcept Therapeutics stock opened at $57.54 on Friday. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. Corcept Therapeutics has a 12-month low of $20.84 and a 12-month high of $61.66. The company has a market capitalization of $6.03 billion, a price-to-earnings ratio of 44.67 and a beta of 0.45. The firm’s 50-day moving average price is $48.02 and its two-hundred day moving average price is $37.65.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm had revenue of $182.55 million during the quarter, compared to analysts’ expectations of $171.97 million. During the same period in the previous year, the firm earned $0.28 EPS. The company’s quarterly revenue was up 47.7% compared to the same quarter last year.

Hedge Funds Weigh In On Corcept Therapeutics

Hedge funds have recently made changes to their positions in the stock. Capital Performance Advisors LLP bought a new position in Corcept Therapeutics during the third quarter worth $25,000. Park Place Capital Corp acquired a new position in shares of Corcept Therapeutics in the 2nd quarter valued at about $32,000. Atwood & Palmer Inc. bought a new stake in shares of Corcept Therapeutics during the 2nd quarter valued at about $35,000. Kathleen S. Wright Associates Inc. acquired a new stake in Corcept Therapeutics during the third quarter worth approximately $36,000. Finally, Blue Trust Inc. increased its holdings in Corcept Therapeutics by 125.4% in the second quarter. Blue Trust Inc. now owns 3,526 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 1,962 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.88, for a total value of $131,736.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William Guyer sold 10,000 shares of Corcept Therapeutics stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $35.30, for a total transaction of $353,000.00. Following the transaction, the insider now owns 6,039 shares in the company, valued at approximately $213,176.70. This trade represents a 62.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,301 shares of company stock worth $1,594,253 in the last 90 days. Insiders own 20.50% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.